Allogene Therapeutics (ALLO) Retained Earnings (2018 - 2026)

Allogene Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$183000.0 in Q1 2026.

• Quarterly Retained Earnings rose 99.99% year-over-year to -$183000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$183000.0 (up 99.99% YoY) and the FY2025 annual result came in at -$2.0 billion, down 2259123.6% from the prior year.
• Retained Earnings improved to -$183000.0 in Q1 2026 per ALLO's latest filing, from -$2.0 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $157000.0 in Q3 2024 and troughed at -$2.0 billion in Q4 2025.
• A 5-year average of -$949.9 million and a median of -$1.1 billion in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 106.51% in 2024, then sank 2259123.6% in 2025.
• Over 5 years, Retained Earnings stood at -$9.9 million in 2022, then sank by 15638.8% to -$1.6 billion in 2023, then surged by 99.99% to -$89000.0 in 2024, then tumbled by 2259123.6% to -$2.0 billion in 2025, then soared by 99.99% to -$183000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$183000.0, -$2.0 billion, and -$2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.